Kodiak Sciences Inc.
KOD
Clasificación en acciones
#3264
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Precio por acción
$85.93
Última sincronización: 2026-10-16
Capitalización bursátil
$5.40B
Cambio (1 día)
-2.49%
Cambio (1 año)
509.40%
País
US
Comercio Kodiak Sciences Inc. (KOD)
Categoría
Healthcare
EPS de Kodiak Sciences Inc. (KOD)
EPS a fecha de June 2026 TTM: $-4.19
Según los últimos informes financieros y el precio de las acciones de Kodiak Sciences Inc., el EPS actual de la empresa (TTM) es $-4.19. Al final del año 2023, la empresa tenía un EPS de $-4.97 una disminución en comparación con al EPS de 2022, que fue de $-6.39.
Historial de EPS de Kodiak Sciences Inc. desde 2016 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-4.19 | 25.07% |
| 2024 | $-3.35 | -32.60% |
| 2023 | $-4.97 | -22.22% |
| 2022 | $-6.39 | 23.84% |
| 2021 | $-5.16 | 77.32% |
| 2020 | $-2.91 | 136.59% |
| 2019 | $-1.23 | 6.03% |
| 2018 | $-1.16 | 10.48% |
| 2017 | $-1.05 | -54.35% |
| 2016 | $-2.30 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -513.37% |
US
|
|
| $-7.98 | 90.45% |
US
|
|
| $-5.29 | 26.25% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -762.05% |
NL
|
